Bioxcel Therapeutics (BTAI) Stock
Clinical biotech developing mental health and cancer treatments. Here's the price, business snapshot, and what's worth knowing about Bioxcel Therapeutics in October 2026.
Bioxcel Therapeutics (BTAI) is a clinical‑stage biotechnology company focused on developing therapies in neuropsychiatric and oncological areas. The company is relatively small, with a market capitalisation around $43.22M, and is typically valued on the progress of early‑stage clinical trials and potential partnerships or licensing deals. Investors should know that outcomes hinge on trial data, regulatory decisions and financing events; small biotechs can be volatile and may dilute equity to fund operations. Bioxcel’s strategy has emphasised efficient drug development and exploring novel therapeutic approaches, but like peers it faces the usual sector risks: clinical failure, regulatory delay and capital constraints. This summary is for educational purposes only and not investment advice. Prospective investors should assess their risk tolerance, review company filings and consider seeking independent financial advice before making any investment decision.
Bioxcel Therapeutics (BTAI) Stock Forecast
Analyst price target, next 12 months
$4.68
+6231.0% vs today's $0.07
Price range over the last 12 months
Close to its 12-month low
Analysts covering Bioxcel Therapeutics have a consensus 12-month target of $4.68, above the current price of $0.07.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 8 Jun 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BIOXCEL's stock with a target price of $4.68, indicating significant potential for growth.
Financial Health
BIOXCEL Therapeutics is generating modest revenue and cash flow, but its profitability is still developing.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Trial catalysts ahead
Clinical data releases and regulatory milestones can move the stock significantly, though results can be binary and outcomes uncertain.
R&D focus and risk
A research‑intensive model can create value if trials succeed, but it also means higher cash burn and potential dilution if financing is needed.
Follow regulatory news
Keep an eye on filings, clinicaltrials.gov updates and company announcements for the clearest signals of progress or setbacks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
